A Real-world Assessment of Healthcare Resource Utilization and Costs among Patients with Agitation Related to Alzheimer's Dementia Living in Private Homes and Residential Facilities
George T Grossberg,Brian Talon,Jeff Schein,Rebecca Bungay,Martin Cloutier,Marjolaine Gauthier-Loiselle,Deborah Chan,Annie Guerin,Jyoti Aggarwal
DOI: https://doi.org/10.1016/j.jagp.2024.01.171
IF: 7.996
2024-02-22
American Journal of Geriatric Psychiatry
Abstract:Introduction Alzheimer's dementia (AD) is characterized by progressive cognitive decline and a range of neuropsychiatric symptoms. Agitation associated with Alzheimer's dementia (AAD) is among the most distressing neuropsychiatric symptoms that can impair an individual's interpersonal relationships, social functioning, and ability to perform everyday activities. Agitation severity has been associated with a higher risk of institutionalization among patients with AD in the United States (US). However, few studies have examined potential differences in the characteristics of patients with AAD, including their agitated behaviors, treatment use, healthcare resource utilization (HRU), and cost burden in different care settings. This subgroup analysis of a broader study aimed to describe these characteristics among patients with AAD living in private homes and residential facilities in the US. Methods The Reliant Medical Group database comprising claims data, electronic medical records, and clinical information abstracted from medical charts was used (01/01/2016-03/31/2020); data were limited to the presumed pre-COVID-19 period to avoid overestimation of HRU burden. Patients with AD aged ≥55 years were identified and observed during a randomly selected 12-month study period after their AD diagnosis. Patients with AAD were defined as those with ≥1 agitated behavior documented in their medical chart during the study period and were stratified into 2 cohorts based on residential settings (i.e., those living in a private home and those living in a residential facility). Patient characteristics, agitated behaviors and treatment, and all-cause and AD-related HRU and healthcare costs during the study period were summarized descriptively for both cohorts. AD-related medical services were identified based on medical claims for which an AD diagnosis was recorded; costs were reported per-patient-per-year (PPPY) in 2021 US dollars. Results A total of 565 patients with AD were identified, including 284 living in private homes and 281 living in residential facilities, among whom 90 (31.7%) and 95 (33.8%), respectively, had ≥1 agitated behavior documented during the study period. Of patients with AAD living in private homes and in residential facilities, respectively, median age was 83 and 89 years; 70.0% and 67.4% were female, and 24.4% and 38.9% had severe AD. Relative to patients with AAD living in private homes, those living in residential facilities were more likely to exhibit aggressive physical and verbal behaviors (private homes: 35.6% and residential facilities: 47.4%) and physically non-aggressive behaviors (34.4% and 43.2%; Table). The most documented aggressive physical and verbal behaviors were hitting (including self) (14.4% and 28.4%), cursing or verbal aggression (13.3% and 14.7%), and screaming (4.4% and 18.9%). For physically non-aggressive behaviors, patients living in residential facilities were more likely to experience general restlessness (private homes: 7.8% and residential facilities: 17.9%) and trying to get to a different place (e.g., out of the room/building) (5.6% and 15.8%); the proportion of patients who exhibited pacing and aimless wandering appeared higher among those living in private homes than in residential facilities (22.2% and 11.6%). In addition, patients with AAD living in residential facility also tended to have more psychiatric comorbidities than those living in private homes (depression: 58.9% and 52.2%; altered mental status: 40.0% and 33.3%; anxiety: 32.6% and 25.6%; delirium: 18.9% and 16.7%, respectively). While these patients were less likely to receive antipsychotic and antidementia medications than those living in private homes, they were more likely to receive anticonvulsants, opioids, and antianxiety (Figure). Patients with AAD living in residential facilities tended to have more all-cause and AD-related inpatient days in hospitals and specialists and physical/occupational/speech therapy visits relative to those living in private homes. The mean ± standard deviation all-cause total healthcare costs were 19,234 PPPY among those living in private homes relatives to 36,063 PPPY among those living in residential facilities. For both cohorts, AD-related medical costs accounted for more than two thirds of these costs (Table). Conclusions Agitation is common among patients with AD, both among those who live in private homes and those who live in residential facilities, with aggressive physical and verbal behaviors and physically non-aggressive behaviors being the most frequently observed. Patients with AAD account for a large clinical and economic burden, as highlighted by th -Abstract Truncated-
psychiatry,geriatrics & gerontology,gerontology